Citations

Clear

1526 citation(s) found for "Sun, C".

IDDF2020-ABS-0181 Disease burden, risk factors, and recent trends of colorectal cancer: a global analysis of data from 186 countries
Huang, Junjie , Patel, Harsh K. , Lucero‐Prisno, Don Eliseo , Boakye, Daniel , Chandrasekar, Viveksandeep Thoguluva , Yuan, Jinqiu , Tse, Shelly LA, Wong, Martin C. S. , Lucero-Prisno, Don Eliseo , Wong, Martin C S , Lok, Veeleah , Liu, Xianjing , Zhang, Lin , Lao, Xiang Qian , Xu, Wanghong , Zheng, Zhi‐Jie

Mayo Clinic

Abstracts | December 17, 2020 | Volume: No volume available | Issue: No issue available | Pages: A5.1-A5

10.1136/gutjnl-2020-iddf.8 Get It

Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial
Perrot, Aurore , Plesner, Torben , Usmani, Saad Z. , Kumar, Shaji , Hulin, Cyrille , Orlowski, Robert Z. , Nahi, Hareth , Mollee, Peter , Ramasamy, Karthik , Roussel, Murielle , Jaccard, Arnaud , Delforge, Michel , Karlin, Lionel, Arnulf, Bertrand , Chari, Ajai , He, Jianming , Ho, Kai Fai, Rampelbergh, Rian Van , Uhlar, Clarissa, Wang, Jianping , Kobos, Rachel, Gries, Katharine S. , Fastenau, John , Orlowski, Robert Z. , Jaccard, Arnaud , Chari, Ajai , Perrot, Aurore , Ramasamy, Karthik , Usmani, Saad , Nahi, Hareth , Roussel, Murielle , Facon, Thierry T.F. , Bahlis, Nizar Jacques , Karlin, Lionel , Weisel, Katja C

Mayo Clinic

Journal of Clinical Oncology | December 16, 2020 | Volume: 39 | Issue: 3 | Pages: 227-237

10.1200/jco.20.01370 | PMID 33326255 Get It

PURPOSE To evaluate the effects of daratumumab, lenalidomide, and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) on patient-reported outcomes (PROs) in the phase III MAIA study. PATIENTS AND METHODS PROs were assessed on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item and the EuroQol 5-dimensional descriptive system at baseline and every 3 months during treatment. By mixed-effects model, changes from baseline are presented as least squares means with 95% CIs. RESULTS A total of 737 transplant-ineligible (TIE) patients with newly diagnosed multiple myeloma were randomly assigned to D-Rd (n = 368) or Rd (n = 369). Compliance with PRO assessments was high at baseline (> 90%) through month 12 (> 78%) for both groups. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item global health status scores improved from baseline in both groups and were consistently greater with D-Rd at all time points. A global health status benefit was achieved with D-Rd, regardless of age (< 75 and ≥ 75 years), baseline Eastern Cooperative Oncology Group (ECOG) performance status score, or depth of response. D-Rd treatment resulted in significantly greater reduction in pain scores as early as cycle 3 ( P = .0007 v Rd); the magnitude of change was sustained through cycle 12. Reductions in pain with D-Rd were clinically meaningful in patients regardless of age, ECOG status, or depth of response. Similarly, PRO improvements were observed with D-Rd and Rd on the EuroQol 5-dimensional descriptive system visual analog scale score. CONCLUSION D-Rd compared with Rd was associated with faster and sustained clinically meaningful improvements in PROs, including pain, in transplant-ineligible patients with newly diagnosed multiple myeloma regardless of age, baseline ECOG status, or depth of treatment response.
Asymmetric caudate hypometabolism in the absence of frontal involvement on FDG‐PET in patients with semantic dementia and behavioral symptoms
Savica, Rodolfo , Radford, Jonathan Graff, Spychalla, Anthony J., Gunter, Jeffrey L. , Lowe, Val J. , Whitwell, Jennifer , Josephs, Keith A. , Choudhury, Parichita , Duffy, Joseph R. , Machulda, Mary M. , Schwarz, Christopher G. , Senjem, Matthew L.

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S5 | Pages: No page available

10.1002/alz.045393 Get It

AbstractBackgroundAlthough semantic dementia (SMD) presents with language decline, patients often develop behavioral changes. Behavioral symptoms in SMD are attributed to both cortical (orbitofrontal cortex atrophy) and subcortical (nucleus accumbens) degeneration in imaging and neuropathological studies. The caudate nucleus has been implicated in early behavioral changes in some phenotypes of frontotemporal dementia. The objective of this study was to determine whether asymmetric ipsilateral caudate nucleus hypometabolism on [18F]‐fluorodeoxyglucose positron emission tomography (FDG‐PET) is associated with early behavioral changes in the absence of frontal hypometabolism in SMD.MethodFifteen patients with a diagnosis of SMD evaluated by the Neurodegenerative Research Group (NRG) at the Mayo Clinic, Rochester from 2006‐2016, who had FDG‐PET, were included in this study. Clinical data was extracted from the medical records including age at presentation, sex, behavioral symptoms and duration of symptoms. Automated average Z‐scores generated from CortexID (GE Healthcare, WI, USA) using 3D stereotactic surface projections were obtained for the following regions bilaterally: temporal lobes, frontal lobes and caudate nucleus. Patients were categorized as left or right hemisphere lateralized based on the higher temporal lobe Z‐scores. Caudate nucleus and frontal lobe Z‐scores were then compared between the two sides for each patient. Hypometabolism was considered present if Z‐scores were greater than 2.ResultOf our cohort, 9/15 (60%) were females with a median age of 68 at presentation and had 3.5 years symptom duration. 13/15 had at least 1 behavioral symptom at presentation. Eleven patients were considered to have left‐lateralized whereas 4 were right‐lateralized in their temporal lobe hypometabolism. Median Z‐scores were significantly different for ipsilateral and contralateral caudate nuclei at 2.5 and 1.6, respectively (p=0.02, Wilcoxon nonparametric test). Frontal lobe median Z‐scores were 1.2 (ipsilateral) and 0.59 (contralateral) with no statistical difference between two sides (p=0.13).ConclusionIn SMD patients who exhibit behavioral symptoms with no frontal hypometabolism on FDG‐PET, asymmetric caudate nuclei hypometabolism should be explored as a possible imaging marker. This implicates abnormal frontal‐striatal circuitry in the development of behavioral symptoms even in the absence of frontal hypometabolism in early behavioral changes in SMD.
Evolution of the core clinical features of dementia with Lewy bodies
Radford, Jonathan Graff, Wurtz, Lincoln , Aakre, Jeremiah A. , Brushaber, Danielle , Knopman, David S. , Savica, Rodolfo , Graff‐Radford, Neill R. , Drubach, Daniel A., Fields, Julie A. , Pedraza, Otto , Forsberg, Leah K. , Allen, Laura A., Miyagawa, Toji , Silber, Michael H. , Petersen, Ronald C. , Choudhury, Parichita , Jones, David T. , Knopman, David S. , Kantarci, Kejal , Machulda, Mary M. , Louis, Erik K. St. , Kremers, Walter K. , Boeve, Bradley F. , Ferman, Tanis J.

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S6 | Pages: No page available

10.1002/alz.044307 Get It

AbstractBackgroundDementia with Lewy Bodies (DLB) is the second most common cause of degenerative dementia but the evolution of the core clinical features of DLB has not been clearly defined. The objective of this study was to identify the temporal relationship between each core feature from the estimated onset of cognitive symptoms.MethodParticipants include 485 patients with probable DLB who were evaluated at the Mayo Clinic Alzheimer Disease Research Center with neurologic and neurocognitive assessment. Each core clinical feature was compared using Kaplan‐Meier (KM) curves with the sentinel event representing age at which each core feature developed, or time from estimated cognitive onset.ResultThe sample was disproportionately male (76%). Patients were followed longitudinally, with 84% followed until death. Mean MMSE at the last evaluation was 18.3 ± 7.8. KM curves for age of onset and cumulative incidence for DLB core features as time from cognitive onset are provided. REM‐sleep behavior disorder (RBD) developed earliest and in 77% of our sample with a median KM survival estimate of 69 years (95% CI: 67.6–70.8). RBD was present in greater than 50% of patients at cognitive symptom onset. The median KM survival estimate for cognitive symptom onset was 70.2 years (95% CI: 69.3‐71.0). Parkinsonism developed in 89% with a median KM survival estimate of 73.7 years (95% CI: 72.7‐74.7). 76% had fluctuations with a similar median KM survival estimate of 74.6 years (95% CI: 73.7‐75.8). Visual hallucinations (VH) were present in 70% emerging at a median KM survival estimate of 80.2 years (95% CI: 79.5‐ 81.3). Cumulative incidence estimates for median time from cognitive onset to parkinsonism, fluctuations and VH were 2 years (95% CI: 2.0‐2.5), 2.3 years (95% CI: 2.0‐3.2) and 4.3 years (95% CI: 4.0‐4.8 years), respectively.ConclusionIn this DLB cohort, RBD was most likely to precede cognitive onset. The evolution of the other core features after cognitive onset was parkinsonism and fluctuations and then VH. While VH occur about 4 years after cognitive symptom onset, parkinsonism and fluctuations occur within the first 2 years.
Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis
Spratt, Daniel E. , Malone, Shawn , Roy, Soumyajit , Grimes, Scott, Eapen, Libni , Morgan, Scott C. , Malone, Julia, Craig, Julia , Dess, Robert T. , Kishan, Amar U. , Mehra, Rohit , Kaffenberger, Samuel D. , Reichert, Zachery R. , Alumkal, Joshi J. , Michalski, Jeff M. , Lee, W. Robert , Pisansky, Thomas M. , Feng, Felix Y. , Shipley, William U. , Schipper, Mathew J., Roach, Mack , Sun, Yilun , Lawton, C.A., Spratt, Daniel E , Dess, Robert T , Jackson, Will , Hartman, Holly , Morgan, Todd M. , Sandler, Howard M.

Mayo Clinic

Journal of Clinical Oncology | December 4, 2020 | Volume: 39 | Issue: 2 | Pages: 136-144

10.1200/jco.20.02438 | PMID 33275486 Get It

PURPOSEThere remains a lack of clarity regarding the influence of sequencing of androgen deprivation therapy (ADT) and radiotherapy (RT) on outcomes in prostate cancer (PCa). Herein, we evaluate the optimal sequencing of ADT with prostate-directed RT in localized PCa.METHODSMEDLINE (1966-2018), Embase (1982-2018), ClinicalTrials.gov, and conference proceedings (1990-2018) were searched to identify randomized trials evaluating the sequencing, but not duration, of ADT with RT. Two randomized phase III trials were identified, and individual patient data were obtained: Ottawa 0101 and NRG Oncology's Radiation Therapy Oncology Group 9413. Ottawa 0101 randomly assigned patients to neoadjuvant or concurrent versus concurrent or adjuvant short-term ADT. Radiation Therapy Oncology Group 9413, a 2 × 2 factorial trial, included a random assignment of neoadjuvant or concurrent versus adjuvant short-term ADT. The neoadjuvant or concurrent ADT arms of both trials were combined into the neoadjuvant group, and the arms receiving adjuvant ADT were combined into the adjuvant group. The primary end point of this meta-analysis was progression-free survival (PFS).RESULTSThe median follow-up was 14.9 years. Overall, 1,065 patients were included (531 neoadjuvant and 534 adjuvant). PFS was significantly improved in the adjuvant group (15-year PFS, 29% v 36%, hazard ratio [HR], 1.25 [95% CI, 1.07 to 1.47], P = .01). Biochemical failure (subdistribution HR [sHR], 1.37 [95% CI, 1.12 to 1.68], P = .002), distant metastasis (sHR, 1.40 [95% CI, 1.00 to 1.95], P = .04), and metastasis-free survival (HR, 1.17 [95% CI, 1.00 to 1.37], P = .050) were all significantly improved in the adjuvant group. There were no differences in late grade ≥ 3 gastrointestinal (2% v 3%, P = .33) or genitourinary toxicity (5% v 5%, P = .76) between groups.CONCLUSIONThe sequencing of ADT with prostate-directed RT has significant association with long-term PFS and MFS in localized PCa. Our findings favor use of an adjuvant over a neoadjuvant approach, without any increase in long-term toxicity.
Targeting nerve growth factor, a new option for treatment of osteoarthritis: a network meta-analysis of comparative efficacy and safety with traditional drugs
Cao, Ziqin , Long, Zeling , Sun, Jingjing, Luo, Yingquan , Wang, Wanchun , Zhou, Jian , Li, Yihan

Mayo Clinic

Aging | December 3, 2020 | Volume: 13 | Issue: 1 | Pages: 1051-1070

10.18632/aging.202232 | PMID 33293475 Get It

International consensus statement on allergy and rhinology: rhinosinusitis 2021
Orlandi, Richard R. , Kingdom, Todd T. , Smith, Timothy L. , Bleier, Benjamin S. , DeConde, Adam S., Luong, Amber , Poetker, David M., Welch, Kevin C. , Wise, Sarah K. , Adappa, Nithin D. , Anselmo‐Lima, Wilma Terezinha , Bachert, Claus , Baroody, Fuad M. , Batra, Pete S., Bernal‐Sprekelsen, Manuel , Bhattacharyya, Neil , Chang, Eugene H., Chowdhury, Naweed I. , Citardi, Martin J. , Cohen, Noah , Conley, David B. , DelGaudio, John M. , Desrosiers, Martin , Douglas, Richard , Eloy, Jean Anderson , Gray, Stacey T. , Gudis, David A. , Hamilos, Daniel L. , Han, Joseph K., Harvey, Richard J. , Hellings, Peter W. , Hopkins, Claire , Hwang, Peter H. , Javer, Amin R. , Kennedy, David W. , Kern, Robert C. , Lee, Heung‐Man , Lee, Jivianne T. , Levy, Joshua M. , Lin, Sandra Y. , Lund, Valerie, McMains, Kevin C. , Metson, Ralph, Naclerio, Robert M. , Oakley, Gretchen M. , Otori, Nobuyoshi , Parikh, Sanjay R., Patel, Zara M. , Peters, Anju T. , Philpott, Carl , Roh, Hwan‐Jung , Rudmik, Luke , Sacks, Raymond , Schlosser, Rodney J. , Sedaghat, Ahmad R. , Senior, Brent A. , Sindwani, Raj , Smith, Kristine A. , Stewart, Michael G. , Suh, Jeffrey D. , Tan, Bruce K. , Drunen, Cornelis M. van , Woodworth, Bradford A. , Wormald, Peter‐John , Wright, Erin D. , Yan, Carol H. , Zhang, Luo , Zhou, Bing , Chang, Michael T. , Bleier, Benjamin , Alt, Jeremiah A , Beswick, Daniel , Eloy, Jean Anderson , Gudis, David A , Holbrook, Eric H , Hopkins, Claire , Javer, Amin R , Jiang, Rong-San , Lal, Devyani , Lee, Heung-Man , Levy, Joshua M , Patel, Zara , Philpott, Carl , Ramakrishnan, Vijay R , Smith, Kristine , Yan, Carol , Zhang, Luo , Schlosser, Rodney J , Harvey, Richard J , Hwang, Peter H , Chang, Michael T , Soler, Zachary M. , Adappa, Nithin D. , Alt, Jeremiah A. , Beswick, Daniel M. , Chandra, Rakesh Kumar , Chang, Eugene H., Chiu, Alexander G. , Cohen, Noam A., Fokkens, Wytske Johanna , Holbrook, Eric H. , Laidlaw, Tanya M. , Lal, Devyani , Lane, Andrew P , Mullol, Joaquim , Passàli, Desiderio , Psaltis, Alkis J. , Ramanathan, Murugappan , Snidvongs, Kornkiat , Turner, Justin H. , Voegels, Richard Louis , Wang, De Yun

Mayo Clinic

International Forum of Allergy & Rhinology | November 25, 2020 | Volume: 11 | Issue: 3 | Pages: 213-739

10.1002/alr.22741 | PMID 33236525 Get It

I. Executive Summary Background The 5 years since the publication of the first International Consensus Statement on Allergy and Rhinology: Rhinosinusitis (ICAR‐RS) has witnessed foundational progress in our understanding and treatment of rhinologic disease. These advances are reflected within the more than 40 new topics covered within the ICAR‐RS‐2021 as well as updates to the original 140 topics. This executive summary consolidates the evidence‐based findings of the document. Methods ICAR‐RS presents over 180 topics in the forms of evidence‐based reviews with recommendations (EBRRs), evidence‐based reviews, and literature reviews. The highest grade structured recommendations of the EBRR sections are summarized in this executive summary. Results ICAR‐RS‐2021 covers 22 topics regarding the medical management of RS, which are grade A/B and are presented in the executive summary. Additionally, 4 topics regarding the surgical management of RS are grade A/B and are presented in the executive summary. Finally, a comprehensive evidence‐based management algorithm is provided. Conclusion This ICAR‐RS‐2021 executive summary provides a compilation of the evidence‐based recommendations for medical and surgical treatment of the most common forms of RS.
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion–Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study
Steensma, David P. , Fenaux, Pierre , Eygen, Koen Van , Raza, Azra , Germing, Ulrich, Font, Patricia , Díez‐Campelo, María , Thépot, Sylvain , Vellenga, Edo , Patnaik, Mrinal M. , Jang, Jun Ho , Varsos, Helen, Bussolari, Jacqueline , Rose, Esther , Sherman, Laurie, Sun, Libo , Wan, Ying , Dougherty, Souria, Huang, Fei , Feller, Faye, Rizo, Aleksandra, Platzbecker, Uwe , Van Eygen, Koen , Font, Patricia , Thepot, Sylvain , Patnaik, Mrinal , Platzbecker, Uwe , Steensma, David P , Diez-Campelo, Maria , Santini, Valeria , Germing, Ulrich

Mayo Clinic

Journal of Clinical Oncology | November 19, 2020 | Volume: 39 | Issue: 1 | Pages: 48-56

10.1200/jco.20.01895 | PMID 33108243 Get It

PURPOSE Patients with lower-risk (LR) myelodysplastic syndromes (MDS) who are RBC transfusion dependent and have experienced relapse after or are refractory to erythropoiesis-stimulating agent (ESA) have limited treatment options. High telomerase activity and human telomerase reverse-transcription expression in clonal hematopoietic cells have been reported in patients with MDS. Imetelstat, a first-in-class competitive inhibitor of telomerase enzymatic activity, targets cells with active telomerase. We report efficacy, safety, and biomarker data for patients with LR MDS who are RBC transfusion dependent and who were relapsed/refractory to ESAs. PATIENTS AND METHODS In this two-part phase II/III study (MDS3001), the primary end point was 8-week RBC transfusion independence (TI) rate, with key secondary end points of 24-week RBC TI rate, TI duration, and hematologic improvement-erythroid. RESULTS Data from the phase II part of the study are reported. Of 57 patients enrolled and treated (overall population), 38 were non-del(5q) and hypomethylating agent and lenalidomide naïve (subset population). The 8- and 24-week RBC TI rates in the overall population were 37% and 23%, respectively, with a median TI duration of 65 weeks. In the subset population, 8- and 24-week RBC TI rates were 42% and 29%, respectively, with a median TI duration of 86 weeks. Eight-week TI rate was observed across all subgroups evaluated. Cytogenetic and mutational data revealed a reduction of the malignant clones, suggesting disease modification activity. The most common adverse events were cytopenias, typically reversible within 4 weeks. CONCLUSION Imetelstat treatment results in a meaningful, durable TI rate across a broad range of heavily transfused patients with LR MDS who are ineligible for or relapsed/refractory to ESAs. Biomarker analyses indicated effects on the mutant malignant clone.
Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance)
Labadie, Julia , Hua, Xinwei , Harrison, Tabitha A. , Banbury, Barbara L. , Huyghe, Jeroen R. , Sun, Wei , Shi, Qian , Yothers, Greg , Sinicrope, Frank A. , Goldberg, Richard M. , George, Thomas J. , Phipps, Amanda I. , Peters, Ulrike , Sinicrope, Frank A , Goldberg, Richard M , George, Thomas J , Cohen, Stacey A , Sun, Wei , Harrison, Tabitha A , Shi, Qian , Yothers, Greg , Alberts, Steven R. , Penney, Kathryn , Cohen, Stacey A. , Chan, Andrew T. , Newcomb, Polly A.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | November 17, 2020 | Volume: 30 | Issue: 2 | Pages: 404-411

10.1158/1055-9965.epi-20-1274 | PMID 33203692 Get It

Abstract Background: Cetuximab, an EGFR inhibitor used to treat multiple cancer types, including colon cancer, causes severe skin toxicity in 5%–20% of patients, leading to decreased quality of life and treatment delays. Our understanding of which patients have an increased risk of severe toxicities is limited. We conducted a genome-wide association study to identify germline variants predictive of cetuximab-induced severe skin toxicity. Methods: Our study included 1,209 patients with stage III colon cancer randomized to receive cetuximab plus 5-fluorouracil and oxaliplatin as part of the NCCTG N0147 (Alliance) clinical trial. Skin toxicity outcomes were collected using the Common Toxicity Criteria for Adverse Events version 3.0. We performed genotyping, evaluating approximately 10 million genetic variants. We used logistic regression to evaluate the association of each genetic variant and severe (grade ≥ 3) skin toxicity, adjusting for age, sex, and genetic ancestry. Genome-wide significance was defined as P &lt; 5 × 10−8. Results: Participants were predominantly middle-aged white men; 20% (n = 243) experienced severe skin toxicity. Two genetic variants in the retinoic acid receptor alpha (RARA) gene were significantly associated with severe skin toxicity [OR, 3.93; 95% confidence interval (CI), 2.47–6.25; P &lt; 7.8 × 10−9]. Functional annotations indicate these variants are in the RARA promoter. Additional significantly associated variants were identified in chromosome 2 intergenic regions. Conclusions: Identified variants could represent a potential target for risk stratification of patients with colon cancer receiving cetuximab. Impact: Retinoids have shown promise in the treatment of cetuximab-induced skin toxicity, so follow-up work could evaluate whether individuals with the RARA variant would benefit from retinoid therapy.
The Diagnostic Value of Cardiac Deceleration Capacity in Vasovagal Syncope
Zheng, Lihui , Sun, Wei , Liu, Shangyu , Liang, Erpeng , Du, Zhongpeng , Guo, Jingrui, Wu, Lingmin , Asirvatham, Samuel J. , Asirvatham, Samuel J , Yao, Yan

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | November 16, 2020 | Volume: 13 | Issue: 12 | Pages: No page available

10.1161/circep.120.008659 | PMID 33197331 Get It

Background: Increased parasympathetic activity is thought to play important roles in syncope events of patients with vasovagal syncope (VVS). However, direct measurements of the vagal control are difficult. The novel deceleration capacity (DC) of heart rate measure has been used to characterize the vagal modulation. This study aimed to assess vagal control in patients with VVS and evaluate the diagnostic value of the DC in VVS. Methods: Altogether, 161 consecutive patients with VVS (43±15 years; 62 males) were enrolled. Tilt table test was positive in 101 and negative in 60 patients. Sixty-five healthy subjects were enrolled as controls. DC and heart rate variability in 24-hour ECG, echocardiogram, and biochemical examinations were compared between the syncope and control groups. Results: DC was significantly higher in the syncope group than in the control group (9.6±3.3 versus 6.5±2.0 ms, P <0.001). DC was similarly increased in patients with VVS with a positive and negative tilt table test (9.7±3.5 and 9.4±2.9 ms, P =0.614). In multivariable logistic regression analyses, DC was independently associated with syncope (odds ratio=1.518 [95% CI, 1.301–1.770]; P =0.0001). For the prediction of syncope, the area under curve analysis showed similar values when comparing single DC and combined DC with other risk factors ( P =0.1147). From the receiver operator characteristic curves for syncope discrimination, the optimal cutoff value for the DC was 7.12 ms. Conclusions: DC>7.5 ms may serve as a good tool to monitor cardiac vagal activity and discriminate VVS, particularly in those with negative tilt table test.